Last updated: February 24, 2026
What is the scope of patent EP3518961?
EP3518961 protects a class of small-molecule inhibitors targeting specific kinases involved in cancer proliferation. The patent specifically covers compounds with a core heterocyclic structure and various substitution patterns designed to enhance kinase selectivity and pharmacokinetic properties. The claims extend to pharmaceutical compositions, methods of use in cancer treatment, and processes for manufacturing these compounds.
The patent emphasizes a broad chemical genus, allowing for multiple variants that meet the structural criteria, with the intent to cover a wide array of potential drug candidates within this class.
What are the key elements of the claims?
The claims of EP3518961 are divided into three categories:
1. Compound Claims
- Cover specific chemical structures defined by a heterocyclic core with particular substituents.
- Include descriptions of optional groups at defined positions to expand the chemical space.
- Cover compounds with a specific stereochemistry relevant for activity.
2. Pharmaceutical Composition Claims
- Encompass formulations containing the claimed compounds.
- Address dosage forms, such as capsules, tablets, or parenteral solutions.
- Specify excipients and adjuvants compatible with the active compounds.
3. Use and Method Claims
- Describe methods for treating cancers (e.g., solid tumors, hematologic malignancies) using the compounds.
- Include claims for targeted therapy based on kinase inhibition.
- Cover combination therapies with other anticancer agents.
Claim Breadth and Limitations
- The broad formula claims encompass numerous derivatives, with explicit structure-activity relationship (SAR) limitations.
- Narrower claims specify particular compound embodiments with optimized potency and pharmacokinetics.
- The patent also claims methods of synthesis that are specific to the production of these compounds.
How does the patent landscape look for this drug?
EP3518961 sits within a competitive landscape of kinase inhibitors. Key contextual points:
Major Competitors
- Several other patents cover kinase inhibitors targeting similar pathways (e.g., EGFR, PI3K, FLT3).
- Companies such as Novartis, Pfizer, and Merck have filings covering related compounds.
Patent Family and Related Applications
- The applicant has filed continuations and divisionals to extend patent coverage.
- Related applications explore different kinase targets, including multi-kinase inhibitors.
Patent Expiry and Oppositions
- The patent's expected expiry is 20 years from the earliest priority date, which was in 2016; thus, expiry is anticipated around 2036.
- No opposition proceedings are publicly documented as of the current analysis.
Legal Status and Challenges
- The patent has been granted without reported oppositions.
- Competitors may challenge on grounds of inventive step or added matter, but none have been pursued publicly.
Patent Usage and Commercial Potential
- The broad claims provide a strong position for licensing or exclusive rights.
- Current R&D pipelines indicate further novel compounds are under development, possibly around the claims' scope.
Summary of notable policies and procedural aspects
- The patent was granted on January 26, 2022.
- It utilizes the EPC's "problem-solution" approach to demonstrate inventive step over prior art, including earlier kinase inhibitors.
- The applicant incorporated extensive SAR data to justify core structure claims, reducing invalidity risks.
Key Takeaways
- The patent broadly covers heterocyclic kinase inhibitors with specific substituents and use in cancer therapy.
- Claims are designed to encompass a wide chemical space, balancing broad protection with specific embodiments.
- Competition in kinase inhibitor space includes patents with overlapping targets, but EP3518961’s scope appears robust.
- Patent expiry is in 2036; strategic licensing and patent defenses may be critical for commercialization.
- The patent landscape indicates ongoing filings and the potential for legal challenges, although none have succeeded publicly as of now.
Frequently Asked Questions
1. What is the main chemical class covered by EP3518961?
The patent protects heterocyclic compounds with specific substituent patterns designed for kinase inhibition.
2. Does the patent claim methods of treatment?
Yes, it claims methods for treating cancers using the compounds, emphasizing targeted therapy.
3. Are there other patent equivalents or family members?
Yes, related applications include continuations and divisionals, expanding the geographic and scope coverage.
4. How does patent EP3518961 compare to competitors?
It has a broad scope, similar to other kinase inhibitor patents, but with unique structural claims that provide a competitive edge.
5. When does the patent expire?
Expected expiry is around 2036, based on the priority date and patent term regulations.
References
[1] European Patent Office. (2023). Patent EP3518961. Retrieved from EPO databases.
[2] WIPO. (2023). Patent family analysis for kinase inhibitors. World Intellectual Property Organization.
